Plays a role in intermediary metabolism and energy production (PubMed:19228619, PubMed:22416140). It may tightly associate or interact with the pyruvate dehydrogenase complex (PubMed:19228619, PubMed:22416140)
Homodimer
A neurometabolic disorder causing developmental delay, epilepsy, hypotonia, and dysmorphic features. Both a mild and a severe phenotype exist. The severe phenotype is homogeneous and is characterized by early infantile-onset epileptic encephalopathy and cardiomyopathy.
The mild phenotype has a more variable clinical presentation. Diagnosis is based on the presence of an excess of D-2-hydroxyglutaric acid in the urine.
Gliomas are benign or malignant central nervous system neoplasms derived from glial cells. They comprise astrocytomas and glioblastoma multiforme that are derived from astrocytes, oligodendrogliomas derived from oligodendrocytes and ependymomas derived from ependymocytes.
Click a pathway to open the interactive Reactome viewer.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to IDH2, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 59
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT03383575 | Acute Myeloid Leukemia, Blasts 20-30 Percent of Bone Marrow Nucleated Cells, Chronic Myelomonocytic Leukemia, IDH2 Gene Mutation, Myelodysplastic Syndrome With Excess Blasts, Recurrent High Risk Myelodysplastic Syndrome, Refractory High Risk Myelodysplastic Syndrome | Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome | PHASE2 | RECRUITING |
| NCT04203316 | Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia | Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation | PHASE2 | ACTIVE_NOT_RECRUITING |
| NCT03878095 | Malignant Solid Neoplasm, Refractory Cholangiocarcinoma, Refractory Malignant Solid Neoplasm | Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors | PHASE2 | ACTIVE_NOT_RECRUITING |
| NCT03914742 | IDH1 Mutation, IDH2 Mutation, Recurrent Glioblastoma, Recurrent WHO Grade II Glioma, Recurrent WHO Grade III Glioma | BGB-290 and Temozolomide in Treating Patients With Recurrent Gliomas With IDH1/2 Mutations | PHASE1, PHASE2 | COMPLETED |
| NCT06387069 | Acute Myeloid Leukemia | A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia | PHASE3 | RECRUITING |
| NCT04603001 | Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Myeloproliferative Neoplasms (MPNs) | Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations | PHASE1 | ACTIVE_NOT_RECRUITING |
| NCT03204838 | Acute Myeloid Leukemia (AML) | IDH1/IDH2 Mutation Frequency in Acute Myeloblastic Patients | N/A | UNKNOWN |
| NCT03515512 | Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | IDH2 Inhibition Using Enasidenib as Maintenance Therapy for IDH2-mutant Myeloid Neoplasms Following Allogeneic Stem Cell Transplantation | PHASE1 | COMPLETED |
| NCT07448480 | Recurrent Malignant Glioma, Glioblastoma, Anaplastic Astrocytoma, Pleomorphic Xanthoastrocytoma | Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas | N/A | ACTIVE_NOT_RECRUITING |
| NCT05592743 | Glioma, Recurrence, Disease Attributes, Pathologic Processes, Neoplasms, Neuroepithelial, Neuroectodermal Tumors, Neoplasms, Germ Cell and Embryonal, Neoplasms by Histologic Type, Neoplasms, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue | Vorasidenib Expanded Access Program | N/A | APPROVED_FOR_MARKETING |